ChromaDex, Inc. Signs Collaboration Research Agreement With St. Jude Children's Research Hospital
IRVINE, Calif., June 19, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.
The collaboration between ChromaDex and St. Jude will focus on screening ChromaDex's natural product libraries against certain biological assays and tumor models with the intent of identifying high value, potentially patentable natural products for specific therapeutic indications. Under the terms of the agreement, ChromaDex will be responsible for providing the natural product libraries for screening, as well as the natural product chemistry expertise to continue the development of any identified candidates into commercial opportunities. St. Jude will screen the natural product libraries provided by ChromaDex, as well as perform other chemical assays to further the characterization of the compounds provided.
"St. Jude is a pioneer in the development of therapies to fight pediatric catastrophic diseases, and with this partnership, we will work to help support their important work," said Frank L. Jaksch, Jr., founder and CEO of ChromaDex. "The ChromaDex catalog offers thousands of unique phytochemical compounds, many of which have never been investigated for their therapeutic potentials. We are excited to start this collaboration with St. Jude, as this program will not only allow ChromaDex to extract value from the natural products library, but also advance pediatric disease research."
About St. Jude Children's Research Hospital:
St. Jude Children's Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other life-threatening diseases. The hospital has played a pivotal role in pushing overall U.S. pediatric cancer survival rates from 20 to 80 percent. Founded by the late entertainer Danny Thomas, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude is also a leader in research and treatment of life-threatening blood disorders and infectious diseases in children. To learn more, visit www.stjude.org.
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY, a caffeine-pTeroPure co-crystal; and NIAGEN, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex Media Inquiries:
ChromaDex Company Contact:
Laura Kelly, Executive Assistant
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
SOURCE ChromaDex Corp.
Help employers find you! Check out all the jobs and post your resume.